XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer

Abstract P4-14-28

Donald A. Bergstrom, Natalya Bodiyak, Peter U. Park, Alex Yuvkovetsky, Michael DeVill, Mao Yin, Laura Polling, Joshua D. Thomas, Dmitry Gumerev, Dongmei Xiao, Elena Ter-Ovanesyan, LiJiang Qin, Alex Uttard, Alex Johnson, Timothy B. Lawinger.
Mersana Therapeutics, Cambridge, MA.

Background
- Advanced breast cancer remains an area of significant unmet medical need.
- HER2+ breast cancer comprises a minority of breast cancer cases.
- The majority of cases express HER2 protein (HER2 3+ or 2+) without HER2 gene amplification and receive a diagnosis of HER2-negative breast cancer.
- Cytotoxic chemotherapy has remained a mainstay of therapy for HER2-amplified breast cancer (HR

Abstract

XMT-1522 is a novel HER2-targeted antibody-drug conjugate (ADC) with a novel payload, dolaflexin, designed to target HER2+ breast cancer. Preclinical studies have shown that XMT-1522 is active in a range of models representing HER2+ breast cancer, including models with low HER2 expression. XMT-1522 demonstrated tumor regressions in preclinical models representing HER2-positive and HER2 low-expressing breast cancer.